SEC Form 4 · accession 0001209191-17-011321
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Lynch
Director
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 8:16 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 14, 2017 | M | 850 | $2.0864 | A | 2,250 | D | |
| Common StockF2 | Feb 14, 2017 | S | 850 | $80.0128 | D | 1,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.0864 | Feb 14, 2017 | M | 850 | D | — | Jul 13, 2021 | Common Stock | 850 | 22,658 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016.
- F2The range of prices for the transaction reported on this line was $80.00 to $80.15. The average weighted price was $80.0128. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option vests over a four-year period in 48 equal monthly installments beginning on April 15, 2011